•
Survival benefit with PD-1/PD-L1 checkpoint inhibitors is independent of histologic subtype.
•
Continued research to identify potential biomarkers beyond histology is needed, for
example
•
Mutational landscape
•
Other immune parameters, eg tumor-infiltrating immune cells,
immune-gene signatures, and ‘Immunoscore’
•
Further research on the role of immune checkpoint inhibitors in subgroups such as
EGFR/ALK-
positive is necessary.
•
Further investigation of PD-L1 as a predictive biomarker is required
•
PD-L1 appears predictive of response to PD-1/PD-L1 inhibitors in some settings
•
PD-L1 low/no expressing patients can still benefit from treatment
To wrap up…
